Drugs / CAR-T/TCR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03941626 | Sep 2019 → May 2021 | esophageal cancer, gastric cancer, glioma, hepatocellular carcinoma | Shenzhen BinDeBio Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T/TCR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03941626 ↗ |
| Modality | Cell therapy | “CAR-T/TCR-T cells immunotherapy” NCT03941626 ↗ |
| Route | Other | “by infusion” NCT03941626 ↗ |